Case report<br>Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)

Agnieszka Owczarczyk-Saczonek; Henryk Witmanowski; Waldemar Placek

doi:10.5114/pdia.2013.35624

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2013
vol. 30

Send email

Copy url:

abstract:

Case report
Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)

Agnieszka Owczarczyk-Saczonek

,

Henryk Witmanowski

,

Waldemar Placek

Postep Derm Alergol 2013; XXX, 3: 195–198

DOI: https://doi.org/10.5114/pdia.2013.35624

Online publish date: 2013/06/20

View full text Get citation

Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with erlotinib.

keywords:

Case reportAcneiform rash during lung cancer therapy with erlotinib (Tarceva®)

Agnieszka Owczarczyk-Saczonek , Henryk Witmanowski , Waldemar Placek

acneiform-rash, erlotynib, tyrosine kinase inhibitors

Case report
Acneiform rash during lung cancer therapy with erlotinib (Tarceva®)

Agnieszka Owczarczyk-Saczonek

,

Henryk Witmanowski

,

Waldemar Placek